Welcome to our dedicated page for Tevogen Bio Holdings SEC filings (Ticker: TVGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Tevogen Bio Holdings's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Tevogen Bio Holdings's regulatory disclosures and financial reporting.
Tevogen Bio Holdings Inc. reported that it received a notice from Nasdaq on September 23, 2025 stating that its common stock no longer meets the Nasdaq Global Market’s $1.00 per share minimum bid price requirement under Listing Rule 5450(a)(1). This determination was based on the stock’s closing bid price over the previous 30 consecutive business days, but the notice does not immediately affect the stock’s listing or trading status.
The company has 180 calendar days, until March 23, 2026, to regain compliance. It will be considered back in compliance if the closing bid price is at least $1.00 per share for a minimum of 10 consecutive business days and generally not more than 20 consecutive business days. If compliance is not restored by that date, Tevogen may seek an additional 180-day period by transferring to the Nasdaq Capital Market and meeting that market’s other initial listing standards.
Tevogen states that it will monitor the closing bid price and the market integrity of its common stock and may evaluate options to regain compliance, but it cautions that there is no assurance it will take any specific action or succeed in maintaining compliance with Nasdaq’s listing rules.